|
|
2014 Featured Talks » Development of BMN 673, a potent and selective poly-(ADP-ribose)polymerase (PARP)-1/2 inhibitor in selected patients with homologous recombination defects
Gilles Gallant, part 1 from MCC Industry Relations on Vimeo.
Gilles Gallant, part 2 from MCC Industry Relations on Vimeo.
Gilles Gallant, BPharm PhD
Vice President, Oncology Clinical Sciences
BioMarin Pharmaceutical Inc.
Dr. Gilles Gallant joined BioMarin Pharmaceutical Inc. (Novato, California) in 2013 as Vice President, Oncology Clinical Sciences. BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
At BioMarin, Dr. Gallant is responsible for the clinical development of BMN 673, a potent poly-(ADP-ribose) polymerase (PARP) inhibitor, currently being studied in a pivotal Phase 3 clinical trial in patients with advanced germline BRCA mutated breast cancer. He is a member of the Executive Committee and the Development Sciences Leadership Team of the Company.
Prior to joining BioMarin, Dr. Gallant was Vice President, Clinical Oncology and then Vice President, Corporate Development at Human Genome Sciences (HGS) Inc. (Rockville, Maryland). At HGS, Dr. Gallant was responsible for establishing the strategy and leading the implementation of the clinical development for all oncology assets including the agonistic monoclonal antibody mapatumumab (targeting the TRAIL-R1 receptor), HGS1029 (a small molecule IAP inhibitor), HGS1036 (fibroblast growth factor (FGF) ligand trap) and other agents in development. He was heading the scientific and clinical evaluation of external opportunities and the competitive intelligence function. Dr. Gallant has been directly involved in the in-licensing of 2 oncology drug candidates as well as the GlaxoSmithKline acquisition. He was an active member of the HGS’ Operating Committee and Senior Management Team.
Prior to joining HGS, Dr. Gallant was Director of Clinical Oncology at Bristol-Myers Squibb (BMS) Pharmaceutical Research Institute (Wallingford, Connecticut). Dr. Gallant joined BMS in 1991, and advanced through a succession of clinical oncology research management positions in Canada, Europe and the United States. Dr. Gallant played a key role in designing and directing worldwide registrational and nonregistrational clinical trials of BMS oncology pipeline. His many achievements include significant contributions leading to the worldwide approval of the blockbuster Taxol®.
Dr. Gallant received his doctorate in medicinal chemistry and bachelor’s degree in pharmacy from the Université de Montréal in Montréal (Québec) Canada. He has coauthored numerous scientific abstracts and peer-reviewed publications in the oncology research field, and is an active member of the Ordre des Pharmaciens du Québec (OPQ), the American Chemical Society (ACS), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the American Society of Hematology (ASH), the International Association for the Study of Lung Cancer (IASLC), the Society of Nuclear Medicine (SNMMI) and the Society of Competitive Intelligence Professionals (SCIP).
|
